Lawrence Eichenfield - 10 Jun 2021 Form 4/A - Amendment Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
VRCA
Transactions as of
10 Jun 2021
Net transactions value
$0
Form type
4/A - Amendment
Filing time
17 Jun 2021, 16:31:13 UTC
Date Of Original Report
14 Jun 2021
Previous filing
01 Jun 2021
Next filing
24 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Stock Option (right to buy) Award $0 +8,109 $0.000000 8,109 10 Jun 2021 Common Stock 8,109 $10.56 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The original Form 4 filed on June 14, 2021 inadvertently listed the incorrect number of options granted to the Reporting Person. This amendment is being file to accurately reflect the true number of options granted.
F2 The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 10, 2021 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date.